Product image of Metylfenidát Neuraxpharm (Methylphenidate Hydrochloride) supplied by GNH India

Metylfenidát Neuraxpharm

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Metylfenidát Neuraxpharm (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride, the active ingredient in Metylfenidát Neuraxpharm, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults.
GNH India supplies Metylfenidát Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Neuraxpharm Bohemia S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metylfenidát Neuraxpharm is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

  • Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves concentration, reduces hyperactivity and impulsivity.
  • Attention deficit hyperactivity disorder (ADHD) in adults: enhances focus and productivity while decreasing distractibility.
  • Narcolepsy: decreases excessive daytime sleepiness and reduces the frequency of cataplexy episodes.

How It Works

  • Methylphenidate hydrochloride blocks the reuptake of dopamine and norepinephrine at presynaptic neuronal membranes, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The heightened dopaminergic and noradrenergic activity in the central nervous system enhances attention, alertness, and executive function, while also reducing the propensity for sudden sleep episodes.

Side Effects

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Decreased appetite: reduced hunger leading to weight loss.
  • Headache: mild to moderate cranial pain.
  • Stomach discomfort: nausea, abdominal pain or dyspepsia.
  • Irritability: increased mood swings or agitation.
  • Elevated heart rate: mild tachycardia.

Serious or Rare Side Effects

  • Cardiovascular events: hypertension, arrhythmia, or myocardial infarction.
  • Psychosis: hallucinations, delusional thinking, or severe agitation.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Priapism: prolonged, painful erection.
  • Seizures: new‑onset convulsive episodes.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for emerging concerns.

  • Cardiovascular assessment: screen for heart disease, hypertension, or structural abnormalities.
  • Psychiatric monitoring: watch for worsening anxiety, mood disorders, or emergence of psychotic symptoms.
  • Growth monitoring: regularly assess weight and height in pediatric patients.
  • Abuse potential: prescribe only when benefits outweigh risk of misuse or dependence.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Methylphenidate can interact with several medication classes, requiring careful review of a patient’s regimen.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Other central nervous system stimulants: additive sympathomimetic effects.
  • Certain antihypertensives: may blunt blood‑pressure‑lowering response.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): possible increase in serotonergic activity.

  • Antipsychotics: may reduce stimulant efficacy.
  • Antihistamines: potential for increased sedation or cardiovascular effects.
  • Alcohol: may exacerbate central nervous system stimulation and cardiovascular strain.

Frequently Asked Questions

Metylfenidát Neuraxpharm contains methylphenidate hydrochloride and is prescribed to manage attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults, as well as to treat narcolepsy by reducing excessive daytime sleepiness and cataplexy episodes.

Methylphenidate blocks the reuptake of dopamine and norepinephrine, increasing their levels in the synaptic cleft. This heightened neurotransmitter activity improves attention, alertness, and impulse control while decreasing the tendency for sudden sleep episodes.

The appropriate dose of Metylfenidát Neuraxpharm is determined individually by a qualified prescriber based on the patient’s age, weight, clinical response, and tolerability. Dosage adjustments are made according to therapeutic goals and safety considerations.

The safety of methylphenidate in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss alternative treatments when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate is a first‑line stimulant for ADHD and differs from non‑stimulant options such as atomoxetine by directly increasing dopamine and norepinephrine levels, often resulting in a faster onset of symptom control. Choice of therapy depends on individual response, side‑effect profile, and comorbid conditions.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

Metylfenidát Neuraxpharm is taken orally, usually once or twice daily as directed by the prescriber. Tablets should be swallowed whole with water and not crushed, chewed, or broken unless specifically instructed.

Serious risks include cardiovascular events such as hypertension or arrhythmia, emergence of psychotic symptoms, severe allergic reactions, priapism, and, in rare cases, seizures. Patients should be monitored closely for these events, especially during treatment initiation or dose changes.

Methylphenidate is contraindicated in individuals with known hypersensitivity to the drug, those taking monoamine oxidase inhibitors, patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychosis without appropriate supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT